PERJETA is indicated for use in combination with Herceptin® (trastuzumab) and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.1

Pertuzumab + trastuzumab (PERJETA + Herceptin) + docetaxel is the only category 1 preferred first-line therapy for patients with HER2+ MBC in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).2*

Learn about the CLEOPATRA trial design, endpoints, and baseline characteristics

See the data from the CLEOPATRA metastatic breast cancer trial

Review the adverse reactions associated with PERJETA + Herceptin-based therapy

Understand the appropriate dosing schedule and duration of treatment

*NCCN Clinical Practice Guidelines in Oncology. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

References